Tuesday, November 11, 2008

Jupiter Study

Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Paul M Ridker, M.D. et al (click here for full article)
Methods: randomly assigned 17,802 healthy men and women with low-density lipoprotein (LDL) cholesterol levels of less than 130 mg per deciliter (3.4 mmol per liter) and high-sensitivity C-reactive protein levels of 2.0 mg per liter or higher to rosuvastatin, 20 mg daily, or placebo.
Results: Rosuvastatin reduced LDL cholesterol levels by 50% and high-sensitivity C-reactive protein levels by 37%. The rates of the primary end point were 0.77 and 1.36 per 100 person-years of follow-up in the rosuvastatin and placebo groups, respectively (hazard ratio for rosuvastatin, 0.56; 95% confidence interval [CI], 0.46 to 0.69; P<0.00001)
Figure 1: endpoint data

Figure 2: hazard ratio


  1. Are the results from a decrease in CRP or from further lowering of LDL's.

  2. Not to be a cynic, but from the article:

    "Dr Ridker...is listed as a coinventor on patents held by Brigham and Women's Hospital that relate to the use of inflammatory biomarkers in cardiovascular disease, including the use of high-sensitivity C-reactive protein in the evaluation of patients' risk of cardiovascular disease."

  3. It's interesting that the baseline HBA1c is 5.7%. It would be nice to have seen fasting and 2h pp levels.


Note: Only a member of this blog may post a comment.